ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

According to results from the phase II NCI9855 study, presented at the 2017 World Congress of Melanoma, glembatumumab vedotin (CDX-011) induced a 61% disease control rate in patients with metastatic uveal melanoma, despite a low a low objective response rate of 6%.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.